🕒 Monday 29 September 2025 Mon, 29 Sept 2025

Chimeric Therapeutics reports encouraging early clinical trial outcomes for its CHM CDH17 CAR-T therapy, showing disease control and tumour shrinkage at higher dose levels with a strong safety profile.

Island Pharmaceuticals has submitted a detailed briefing to the FDA aiming to accelerate approval of its antiviral Galidesivir for Marburg virus under the Animal Rule, with feedback expected by November.

Pioneer Lithium has raised $750,000 through a well-supported placement featuring director participation and a board reshuffle, aiming to fuel exploration and project development.

Elixir Energy has commenced drilling the Diona-1 conventional gas-oil exploration well in Queensland’s Surat-Bowen Basin, aiming to unlock new production potential and secure long-term asset retention.

Black Rock Mining has secured A$10 million through an equity placement to initiate early construction activities at its Mahenge Graphite Project in Tanzania, marking a pivotal step towards full project development.

Dynamic Metals Limited has identified a significant gold-in-soil anomaly at its Courvoisier prospect within the Widgiemooltha Project, signalling promising potential for bedrock-hosted gold mineralisation. Meanwhile, assay results from recent drilling at Chalice South are eagerly awaited.

Desert Metals has confirmed significant gold mineralisation over a 1.2km strike at its King Kong prospect in Côte d’Ivoire, underpinning plans for expanded exploration across its Adzope project.

Bravura Solutions has appointed Colin Greenhill as its new Group CEO, effective 1 January 2026, following a comprehensive global search. Greenhill brings over 15 years of leadership experience in financial services software, signaling a strategic step forward for the company.

Mustang Energy has initiated a significant 2,000-metre diamond drilling campaign at the Surprise Creek Uranium-Copper Project in Canada’s Athabasca Basin, aiming to extend previously identified high-grade uranium mineralisation.

Broken Hill Mines has completed underground access to the high-grade Main Lode ore body at its Rasp Mine, delivering exceptional drilling results and targeting first ore extraction by November 2025.

EMVision Medical Devices launches a $2 million Share Purchase Plan offering shares at a 16.4% discount, bundled with free options exercisable at $3.40, aiming to bolster clinical and commercial milestones.

Critica Limited reports strong preliminary beneficiation results from its Jupiter rare earths project, achieving consistent ~95% mass rejection and a 6–10x uplift in rare earth grades. A closed-circuit pilot plant is now under construction to optimise recovery and advance product development.

Dreadnought Resources has revealed a significant rare earth element discovery at its Stinger niobium deposit within the Gifford Creek Carbonatite, marking a new high-grade target in its Mangaroon Critical Metals project.

Terrain Minerals has reported robust high-grade gold intersections from its latest drilling at the Lightning prospect within the Smokebush Project, reinforcing the potential for a significant new gold system in Western Australia.

S2 Resources has significantly expanded its Jillewarra project area over a highly prospective gold shear zone and completed drilling at West Murchison, with assay results pending. Meanwhile, Glenlogan assays returned no significant mineralisation.

Rent.com.au reports strong early success with its RentBond® loan product, doubling loan volumes in September and drawing down a second $1 million tranche from its $10 million funding facility with Eldium.

Synlait Milk Limited reports a modest profit turnaround in FY25 and announces a major sale of its North Island assets to Abbott, aiming to reduce debt and sharpen its focus on core operations.

Synlait has agreed to sell its North Island assets to global healthcare giant Abbott for approximately US$178 million, marking a strategic reset focused on debt reduction and operational simplification. The deal, expected to close by April 2026, positions Synlait to concentrate on its South Island operations and explore new growth avenues.

Synlait Milk Limited reported an 11.7% rise in revenue to NZD 1.83 billion for the year ending July 2025, yet its net loss deepened sharply to nearly NZD 40 million, prompting a halt on dividends.